Omeros said that OMS302 is its proprietary PharmacoSurgery product in development to maintain mydriasis (pupil dilation) and reduce postoperative pain and inflammation following cataract and other lens replacement surgery.
In the trial, the first arm is expected to receive OMS302, whereas the second and third will receive only the mydriatic agent and the anti-inflammatory agent, respectively, and the fourth arm will receive a placebo of standard irrigation solution without drug.
Reportedly, a prior Phase 1/Phase 2 clinical trial of 61 patients undergoing age-related cataract extraction with lens replacement showed that patients treated with OMS302 reported less postoperative pain and demonstrated improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control.